Mark Rogge

Mark Rogge is an Adjunct Professor in the Department of Pharmaceutics at the University of Florida. He specializes in pharmacometrics, clinical pharmacology, and drug development with a focus on translational research in oncology, hematology, and neurology. His work integrates population pharmacokinetic modeling, biomarker analysis, and therapeutic innovation.

Dr. Rogge teaches 'Model-Informed Drug Development' (PHA6418) and has contributed to over 20 years of research. His grants include a 2021-2023 Takeda Research Agreement as Co-Project Director/Principal Investigator. Notable research areas include antisense oligonucleotide pharmacology, RNA-targeted therapeutics, and PK/PD modeling for biologics.

Key publications span topics from myeloma treatment biomarkers to spinal muscular atrophy therapies, demonstrating expertise in both small molecules and biopharmaceuticals. His work emphasizes drug delivery mechanisms, safety profiling, and regulatory aspects of protein therapeutics.